The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells
Abstract
Proteinase 3 is present in high concentration in the primary granules of acute and chronic myeloid leukemia blasts, and may represent a potential T-cell target antigen. We screened proteinase 3 against the binding motif of HLA-A2.1. Based on its high predicted binding, a 9-mer peptide, “PR-1,” was synthesized and tested for binding to HLA-A2.1 using the T2 cell line. PR-1 at 100 micrograms/mL significantly increased expression of HLA-A2.1, with median channel of fluorescence increasing from 22 to 294. Binding half-life was determined to be 1,460 minutes by I125-labeled beta 2-microglobulin incorporation. HLA-A2.1+ peripheral blood mononuclear cells from a normal donor were used to generate a T-cell line specific for PR-1. The line demonstrated 85% PR-1-specific lysis at an E:T ratio of 50:1, compared with 20% lysis without PR-1, using T2 cells as targets. It also showed 79% specific lysis to fresh chronic myelogenous leukemia blasts, 54% to fresh acute myelogenous leukemia blasts, and only background lysis (< 20%) to HLA-A2.1+ normal allogeneic marrow cells. The amount of lysis of HLA-A2.1+ myeloid cells was proportional to cytoplasmic proteinase 3 expression. Thus, HLA-A2.1-restricted cytotoxic T cells, raised against a peptide contained in proteinase 3, preferentially lysed fresh human leukemic cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MHC ligands and peptide motifs: first listing
Rammensee, H.-G., Friede, T., & Stevanović, S. (1995) · Immunogenetics · doi:10.1007/bf00172063 · Cited by 1,638
Tumor Antigens Recognized by T Lymphocytes
Boon, T., Cerottini, J.-C., Van den Eynde, B., van der Bruggen, P., & Van Pel, A. (1994) · Annual Review of Immunology · doi:10.1146/annurev.iy.12.040194.002005 · Cited by 1,221
Kawakami, Y., Eliyahu, S., Delgado, C. H., Robbins, P. F., Sakaguchi, K., Appella, E., Yannelli, J. R., Adema, G. J., Miki, T., & Rosenberg, S. A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.14.6458 · Cited by 914
Mackinnon, S., Papadopoulos, E., Carabasi, M., Reich, L., Collins, N., Boulad, F., Castro-Malaspina, H., Childs, B., Gillio, A., & Kernan, N. (1995) · Blood · doi:10.1182/blood.v86.4.1261.bloodjournal8641261 · Cited by 722
Peoples, G. E., Goedegebuure, P. S., Smith, R., Linehan, D. C., Yoshino, I., & Eberlein, T. J. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.2.432 · Cited by 439
Goldschmeding, R., van der Schoot, C. E., ten Bokkel Huinink, D., Hack, C. E., van den Ende, M. E., Kallenberg, C. G., & von dem Borne, A. E. (1989) · Journal of Clinical Investigation · doi:10.1172/jci114335 · Cited by 432
Cancer antigens: immune recognition of self and altered self.
Houghton, A. N. (1994) · The Journal of experimental medicine · doi:10.1084/jem.180.1.1 · Cited by 420
van der Burg, S. H., Visseren, M. J., Brandt, R. M., Kast, W. M., & Melief, C. J. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.156.9.3308 · Cited by 394
MHC Ligands and Peptide Motifs
Rammensee, H.-G., Bachmann, J., & Stevanović, S. (1997) · Molecular Biology Intelligence Unit · doi:10.1007/978-3-662-22162-4 · Cited by 331
Bories, D., Raynal, M.-C., Solomon, D. H., Darżynkiewicz, Z., & Cayre, Y. E. (1989) · Cell · doi:10.1016/0092-8674(89)90752-6 · Cited by 314
Cited by
Molldrem, J. J., Lee, P. P., Wang, C., Felio, K., Kantarjian, H. M., Champlin, R. E., & Davis, M. M. (2000) · Nature Medicine · doi:10.1038/79526 · Cited by 672
Self-citationGraft-versus-leukemia effects of transplantation and donor lymphocytes
Kolb, H.-J. (2008) · Blood · doi:10.1182/blood-2008-03-077974 · Cited by 582
The Pathophysiology of Acquired Aplastic Anemia
Young, N. S., & Maciejewski, J. (1997) · New England Journal of Medicine · doi:10.1056/nejm199705083361906 · Cited by 505
Haematopoietic cell transplantation as immunotherapy
Appelbaum, F. R. (2001) · Nature · doi:10.1038/35077251 · Cited by 411
Graft-versus-leukemia reactions in allogeneic chimeras
Kolb, H.-J., Schmid, C., Barrett, A. J., & Schendel, D. J. (2004) · Blood · doi:10.1182/blood-2003-02-0342 · Cited by 397
Self-citation
Metadata
- Authors
- Molldrem, J., Dermime, S., Parker, K., Jiang, Y., Mavroudis, D., Hensel, N., Fukushima, P., & Barrett, A.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 1996-10-01
- Volume
- 88
- Issue
- 7
- Pages
- 2450-2457
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W998391454
- Cited by
- 325
- References
- 20
- FWCI
- 2.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. https://app.cochat.ai/papers/10.1182/blood.v88.7.2450.bloodjournal8872450
- The paper
- Molldrem, J., Dermime, S., Parker, K., Jiang, Y., Mavroudis, D., Hensel, N., Fukushima, P., & Barrett, A. (1996). Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. Blood. https://doi.org/10.1182/blood.v88.7.2450.bloodjournal8872450
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.